A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

PURPOSE: AZD6244 is a MEK1/2 inhibitor with significant preclinical activity in multiple myeloma (MM) cells. This phase 2 study used a two-stage Simon design to determine the AZD6244 response rate in patients with relapsed or refractory MM. EXPERIMENTAL DESIGN: AZD6244 (75 mg) was administered orall...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Holkova, Beata, Zingone, Adriana, Kmieciak, Maciej, Bose, Prithviraj, Badros, Ashraf Z., Voorhees, Peter M., Baz, Rachid, Korde, Neha, Lin, Hui-Yi, Chen, Jin-Qiu, Herrmann, Michelle, Xi, Liqiang, Raffeld, Mark, Zhao, Xiuhua, Wan, Wen, Tombes, Mary Beth, Shrader, Ellen, Weir-Wiggins, Caryn, Sankala, Heidi, Hogan, Kevin T., Doyle, Austin, Annunziata, Christina M., Wellons, Martha, Roberts, John D., Sullivan, Daniel, Landgren, Ola, Grant, Steven
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775365/
https://ncbi.nlm.nih.gov/pubmed/26446942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1076
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki